Stunning Start For Vertex Cystic Fibrosis Triple Combo
Trikafta Shatters Forecasts With Q4 $420m Sales
Only nine weeks after US approval, Trikafta, which in theory can treat 90% of all patients with cystic fibrosis, is already Vertex's top-selling medicine.
